Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up
03:36pm, Friday, 25'th Feb 2022 Zacks Investment Research
Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.
Medicare’s finances and the saga of the Alzheimer's drug Aduhelm
06:41pm, Thursday, 24'th Feb 2022 MarketWatch
The program is vulnerable to expensive new drugs
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
05:03pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental Education, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm
02:00am, Thursday, 24'th Feb 2022 GlobeNewswire
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of New Oriental Education & Technology Group, Inc. (NYSE: EDU), Biogen, Inc. (NASDAQ: BIIB), Telos Corporation (NASDAQ: TLS), and Fennec Pharmaceuticals, Inc. (NASDAQ: FENC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
What Investors Can Learn From Biogen's Drug Approval That No One Wants
09:32pm, Wednesday, 23'rd Feb 2022 The Motley Fool
Will Aduhelm's controversial approval signal a new normal for clinical trials?
What Investors Can Learn From Biogen''s Drug Approval That No One Wants
09:32pm, Wednesday, 23'rd Feb 2022 The Motley Fool
Will Aduhelm''s controversial approval signal a new normal for clinical trials?
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
05:57pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers
05:57pm, Wednesday, 23'rd Feb 2022 The Wall Street Journal
The agency proposed limiting coverage of Biogen’s Aduhelm to patients enrolled in government-sanctioned clinical trials, a decision that would also apply to similar drugs being developed by rival firms.
Medicare Proposal on Alzheimer''s Drug Draws Criticism From Drugmakers
05:57pm, Wednesday, 23'rd Feb 2022 The Wall Street Journal
The agency proposed limiting coverage of Biogen’s Aduhelm to patients enrolled in government-sanctioned clinical trials, a decision that would also apply to similar drugs being developed by rival firms.
What Investors Can Learn From Biogen's Drug Approval That No One Wants
04:32pm, Wednesday, 23'rd Feb 2022
Will Aduhelm's controversial approval signal a new normal for clinical trials?
The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022
04:04pm, Wednesday, 23'rd Feb 2022 iCrowdNewswire
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 7, 2021 and January 11, 2022. If you suffered a loss on your investment in Biogen, contact us about potential recovery by using []
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firms Attorneys, Securities Class Action Filed
02:33pm, Tuesday, 22'nd Feb 2022 GlobeNewswire
SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Biogen Inc. (NASDAQ: BIIB) investors with significant losses to submit your losses now . A securities fraud class action has been filed and certain investors may have valuable claims.
NEW YORK, Feb. 19, 2022 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Biogen, Inc. (Biogen or the Company) (NASDAQ: BIIB) and reminds investors of the April 8, 2022 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Could Advocacy Groups' Campaign for Aduhelm Benefit Biogen?
12:55pm, Saturday, 19'th Feb 2022 The Motley Fool
It's possible.
Could Advocacy Groups'' Campaign for Aduhelm Benefit Biogen?
12:55pm, Saturday, 19'th Feb 2022 The Motley Fool
It''s possible.
